Episode 75

Advancing MS Research in Australia: Innovation, impact and the case for greater investment

Join us for a special episode of the Raw Nerve Podcast as we celebrate excellence in MS Australia research, showcase exciting projects from our most recent MS Research Grant Round, and discuss the need for greater government investment in neurological research.

MS Australia has invested millions into funding and facilitating MS research in Australia and around the globe. Outside of government, we are the largest funder of MS research in Australia, having invested over $75 million to date.

In this episode of the Raw Nerve podcast we take you to Parliamentary Friends of MS event at Parliament House Canberra.

You’ll hear from Parliamentary Friends of MS Co-Chairs Senator Wendy Askew and Senator Deborah O’Neill and explore MS Australia’s research program with Dr Tennille Luker, Head of Research at MS Australia. Member for Griffith, Renee Coffey MP speaks about the value of MS research through the lens of lived experience and political representation. And Dr Monique Ryan, Independent Member for Kooyong discusses the critical importance of medical research and the need to unlock and invest more Commonwealth funding.

Useful links:

Episode Transcript

The episode transcript is unavailable at this time.

Click here to watch the video

Views expressed on the Raw Nerve Podcast, including any discussions or reference to medications or treatments by podcast guests, do not necessarily represent the views of MS Australia and should not be seen as either an endorsement or rejection of a treatment.

MS Australia does not recommend any specific treatment for people living with MS. Decisions about any treatments, taking into consideration the potential benefits and side effects for each individual’s circumstances, should be made in careful consultation with the person’s neurologist.

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

Advancing MS Research in Australia: Innovation, impact and the case for greater investment